Pivarubicin Is More Effective Than Doxorubicin Against Triple-Negative Breast Cancer In Vivo

Triple-negative breast cancer (TNBC) is unresponsive to antiestrogen and anti-HER2 therapies, requiring the use of cytotoxic drug combinations of anthracyclines, taxanes, cyclophosphamide, and platinum compounds. Multidrug therapies achieve pathological cure rates of only 20–40%, a consequence of dr...

Descripción completa

Detalles Bibliográficos
Autores principales: Lothstein, Leonard, Soberman, Judith, Parke, Deanna, Gandhi, Jatin, Sweatman, Trevor, Seagroves, Tiffany
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cognizant Communication Corporation 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7751225/
https://www.ncbi.nlm.nih.gov/pubmed/32430093
http://dx.doi.org/10.3727/096504020X15898794315356

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7751225/
https://www.ncbi.nlm.nih.gov/pubmed/32430093
http://dx.doi.org/10.3727/096504020X15898794315356

Ejemplares similares